Oligodendroglioma CT

Oligodendroglioma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Oligodendroglioma from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Staging
History & Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Oligodendroglioma CT On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Oligodendroglioma CT All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Oligodendroglioma CT
CDC on Oligodendroglioma CT
Oligodendroglioma CT in the news
Blogs on Oligodendroglioma CT
Directions to Hospitals Treating Oligodendroglioma
Risk calculators and risk factors for Oligodendroglioma CT

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

CT

• Oligodendrogliomas typically manifest as a round or oval sharply marginated mass involving the cortex or subcortical white matter at cross-sectional neuroimaging.
• At computed tomography, about 60% are hypoattenuating while 23% are isoattenuating and about 6% are hyperattenuating.
• Calcification is noted in 20%–91% of cases.
• Subtle ill-defined enhancement following intravenous contrast material administration is seen in 15%–20% of oligodendrogliomas and is associated with higher-grade tumors.

Gallery

• 
  Heterogeneous region of contrast enhancement, oedema and mass effect is present in the left frontal lobe.